Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
暂无分享,去创建一个
[1] C. Massone,et al. The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts , 2022, Cancers.
[2] C. Dessinioti,et al. Overview of guideline recommendations for the management of high‐risk and advanced cutaneous squamous cell carcinoma , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.
[3] R. Dummer,et al. Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma , 2021, Oncotarget.
[4] C. Garbe,et al. Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany , 2021, Acta dermato-venereologica.
[5] P. Ascierto,et al. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. , 2021, European journal of cancer.
[6] R. Dummer,et al. 1089TiP Efficacy and tolerability of anti-PD1 antibody in combination with pulsed hedgehog inhibitor in advanced basal cell carcinoma , 2021, Annals of Oncology.
[7] J. Haanen,et al. 1062P Real-world data on clinical outcome and tolerability in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in the Netherlands , 2021, Annals of Oncology.
[8] G. Daniels,et al. 1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS] , 2021, Annals of Oncology.
[9] K. Kähler,et al. 1095TiP Daromun, a dermato-oncology drug in development for stage III and IV melanoma and non-melanoma skin cancers: A clinical overview , 2021, Annals of Oncology.
[10] A. Hauschild,et al. 1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results , 2021, Annals of Oncology.
[11] A. Hauschild,et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis , 2021, Journal for ImmunoTherapy of Cancer.
[12] S. Billan,et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Jason M. Johnson,et al. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck , 2021, Clinical Cancer Research.
[14] A. Hauschild,et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. , 2021, The Lancet. Oncology.
[15] T. Ow,et al. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp , 2021, Current oncology.
[16] K. Harrington,et al. 422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts , 2020 .
[17] R. Fontana,et al. A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. , 2020, The oncologist.
[18] P. Petrow,et al. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] K. Davies,et al. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy , 2020, Cancer medicine.
[20] I. Lowy,et al. A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC). , 2020 .
[21] C. Berking,et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. , 2020, The Lancet. Oncology.
[22] P. Mohr,et al. Estimating prevalence and incidence of skin cancer in Germany , 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[23] S. Arron,et al. Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.
[24] R. Birhiray,et al. Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation. , 2019, Journal of oncology practice.
[25] C. Schmults,et al. Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women's Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. , 2019, JAMA dermatology.
[26] Helen X. Chen,et al. SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. , 2019, Journal of Clinical Oncology.
[27] G. Daniels,et al. KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma. , 2019, Journal of Clinical Oncology.
[28] J. Taube,et al. A phase 2 study of nivolumab (NIVO) alone or plus ipilimumab (IPI) for patients with locally advanced unresectable (laBCC) or metastatic basal cell carcinoma (mBCC). , 2019, Journal of Clinical Oncology.
[29] Ansuman T. Satpathy,et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study , 2018, Journal of the American Academy of Dermatology.
[30] P. Lefrançois,et al. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta‐analysis , 2018, Journal of the American Academy of Dermatology.
[31] H. C. de Vijlder,et al. Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study , 2018, The British journal of dermatology.
[32] A. Sisk,et al. PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin – case report , 2018, BMC Nephrology.
[33] A. Hauschild,et al. PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma , 2018, The New England journal of medicine.
[34] Helen X. Chen,et al. A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057). , 2018 .
[35] J. Califano,et al. Comparison of Tumor Classifications for Cutaneous Squamous Cell Carcinoma of the Head and Neck in the 7th vs 8th Edition of the AJCC Cancer Staging Manual , 2017, JAMA dermatology.
[36] K. May,et al. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature , 2016, American journal of clinical oncology.
[37] T. Chan,et al. The role of neoantigens in response to immune checkpoint blockade. , 2016, International immunology.
[38] R. Dummer,et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. , 2015, The Lancet. Oncology.
[39] A. Chang,et al. Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations , 2014, Current Dermatology Reports.
[40] A. Qureshi,et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] R. Dummer,et al. Basal cell carcinoma: a paradigm for targeted therapies , 2013, Expert opinion on pharmacotherapy.
[42] W. Hwang,et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. , 2013, JAMA dermatology.
[43] E. Dennett,et al. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors , 2012, Journal of surgical oncology.
[44] Aleksandar Sekulic,et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.
[45] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[46] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[47] J. Higginson,et al. International Agency for Research on Cancer. , 1968, WHO chronicle.